Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 5/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311767 | 0.93 | IL2 (0.47) | IL2ABCB1ABCC1LMNAMEN1 | |
| SCHEMBL2314656 | 0.93 | ABCB1 (0.46) | IL2ABCB1ABCC1LMNAMEN1 | |
| SCHEMBL2312220 | 0.84 | IL2 (0.48) | IL2LMNAMEN1POLBKMT2A | |
| SCHEMBL2315252 | 0.83 | LMNA (0.51) | IL2ABCB1LMNAMEN1POLB | |
| SCHEMBL2851676 | 0.82 | IL2 (0.46) | IL2LMNAGCKDYRK1ADYRK1B | |
| SCHEMBL7917075 | 0.82 | LMNA (0.52) | IL2LMNAMEN1KMT2ADYRK1A | |
| SCHEMBL2314051 | 0.79 | ABCB1 (0.46) | IL2ABCB1ABCC1LMNAGCK | |
| SCHEMBL2313550 | 0.77 | IL2 (0.48) | IL2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL7928542 | 0.77 | IL2 (0.48) | IL2MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL7924145 | 0.75 | ABCB1 (0.46) | IL2ABCB1ABCC1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165451-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120283272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283272-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885ABCB1 574/4885ABCC1 473/4885 |
| US-20130165451-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | IL2 11/4885ABCB1 574/4885ABCC1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.